Patents Assigned to Glaxo Group Ltd.
-
Publication number: 20120004160Abstract: The present invention relates to agents, and methods for identifying compounds, which agents and compounds result in the inhibition of the activation of macrophages. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by activation of macrophages including infections, allograft reactions, inflammation, allergic and autoimmune diseases, metabolic disease, cardiovascular disease, tissue injury, and cancer.Type: ApplicationFiled: February 18, 2010Publication date: January 5, 2012Applicants: Glaxo Group Ltd., Bio-Focus DPI B.V.Inventors: Richard Antonius Jozef Janssen, Anton De Groot, Annemarie Nicolette Lekkerkerker, Eric Charles Meldrum, Nicola Thompson, Marion Catherine Dickson, Keith Paul Ray, Susan Heather Boyce
-
Patent number: 7718621Abstract: A compound of formula (I) or a pharmaceutically acceptable derivative thereof, having antimicrobial activity, processes for their preparation, compositions containing them and to their use in medicine.Type: GrantFiled: November 9, 2005Date of Patent: May 18, 2010Assignees: Glaxo Group Ltd., Pliva-Istrazivacki InstitutInventors: Desmond John Best, John Stephen Elder, Andrew Keith Forrest, Robert John Sheppard, Andrea Fajdetic
-
Patent number: 6032835Abstract: An aerosol dispenser is provided which comprises a body (1), a closure (2) sealed to the body (1), and propellant (7) for dispensing material from the interior of the dispenser. The closure (2) is welded to the body (1) by a metal-to-metal weld. Preferably the welding is carried out ultrasonically. A method for assembling the aerosol dispenser is also provided.Type: GrantFiled: September 9, 1998Date of Patent: March 7, 2000Assignee: Glaxo Group Ltd.Inventor: Peter Colin Weston Burt
-
Patent number: 5399556Abstract: The invention relates to salts formed between ranitidine and a complex of zinc with a carboxylic acid selected from tartaric acid, citric acid and alkyl citric acids, and to solvates of such salts. The salts and solvates thereof are useful in the treatment of gastro-intestinal disorders, such as peptic ulcer disease and non-ulcer dyspepsia.Type: GrantFiled: March 2, 1992Date of Patent: March 21, 1995Assignee: Glaxo Group Ltd.Inventors: John W. Clitherow, Eric W. Collington
-
Patent number: 5243076Abstract: Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12;Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group;R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4;and the physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients.The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.Type: GrantFiled: December 19, 1991Date of Patent: September 7, 1993Assignee: Glaxo Group Ltd.Inventors: Ian F. Skidmore, Lawrence H. C. Lunts, Harry Finch, Alan Naylor
-
Patent number: 5225445Abstract: Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12;Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group;R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4;and the physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients.The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.Type: GrantFiled: February 19, 1992Date of Patent: July 6, 1993Assignee: Glaxo Group Ltd.Inventors: Ian F. Skidmore, Lawrence H. C. Lunts, Harry Finch, Alan Naylor
-
Patent number: 5126375Abstract: Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12;Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group;R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and the physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients.The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.Type: GrantFiled: November 29, 1990Date of Patent: June 30, 1992Assignee: Glaxo Group Ltd.Inventors: Ian F. Skidmore, Lawrence H. C. Lunts, Harry Finch, Alan Naylor
-
Patent number: 4992474Abstract: Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12;Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group;R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4;and the physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients.The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.Type: GrantFiled: August 23, 1989Date of Patent: February 12, 1991Assignee: Glaxo Group Ltd.Inventors: Ian F. Skidmore, Lawrence H. C. Lunts, Harry Finch, Alan Naylor
-
Patent number: 4963564Abstract: The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts and solvates thereof, wherein Z represents the group ##STR2## (wherein Q.sup.1 represents a straight or branched C.sub.1-3 alkylene group), ##STR3## (where Q.sup.2 represents a group R.sup.5 CO--, R.sup.5 NHCO--, R.sup.5 R.sup.6 NSO.sub.2 -- or R.sup.7 SO.sub.2 --, where R.sup.5 and R.sup.6 each represent a hydrogen atom or a C.sub.1-3 alkyl group, and R.sup.7 represents a C.sub.1-3 alkyl group), or ##STR4## X represents a bond, or a C.sub.1-7 alkylene, C.sub.2-7 alkenylene or C.sub.2-7 alkynylene chain, and Y represents a bond, or a C.sub.1-6 alkylene, C.sub.2-6 alkenylene or C.sub.2-6 alkynylene chain with the proviso that the sum total of carbon atoms in the chains X and Y is not more than 10;R represents a hydrogen atom or C.sub.1-3 alkyl group;R.sup.1 and R.sup.2 each represent a hydrogen atom or a C.sub.1-3 alkyl group; with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.Type: GrantFiled: August 10, 1988Date of Patent: October 16, 1990Assignee: Glaxo Group Ltd.Inventors: Ian F. Skidmore, Alan Naylor, Harry Finch, Lawrence H. C. Lunts, Ian B. Campbell